Clinical Research Directory

Inclusion Criteria: * • Patients \>60 \<75 years of age * Diagnosis of AML eligible for allo-SCT from any donor * High- and Intermediate-Risk ELN * WBC \<25x109/L (Hydroxyurea is permitted to meet this criterion) * adequate hepatic function (bilirubin ≤2 UNL; ALT/AST ≤2,5 UNL) * adequate renal function (creatinine clearance ≥50 ml/min) * ECOG Performance Status \< 2 * Males enrolled in the study with partners who are women of childbearing potential, must be willing to use an acceptable barrier contraceptive method during the trial. * Women of childbearing potential must use highly effective contraception for at least 1 month after the last dose of VEN and for however long the EU SmPC says for DEC * Willing and able to comply with all of the requirements and visits in the protocol. * Written and signed informed consent. Exclusion Criteria: * • Previous treatment for AML (Hydroxyurea is allowed) or for an antecedent Myelodysplastic Syndrome (MDS). * Absence of informed consent * AML patients with t(15;17); t(8;21); inv(16) * Subject has known active CNS involvement with AML. * Low Risk ELN * grade \>2 NCI-CTCAE (v. 5) adverse events at the time of enrollment * Serious organ dysfunction: left ventricular ejection fraction \< 40%, FEV1, FVC, DLCO (diffusion capacity) \<40% of predicted, LFT \> 5 times the upper limit of normal, or creatinine clearance \< 40 ml/min. * The evidence of HBV or HCV active infection (HBV DNA HCV RNA positive test). * Patients with HIV infection * Current uncontrolled infections * Patients with other life-threatening concurrent disease * Subjects with known hypersensitivity to any of the component medication * Subject has a history of other malignancies within 2 years prior to study entry, with the exception of: * Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; * Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent. • Participation in another clinical trial within 1 month before the start of this trial